<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02707393</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT 2008-000569-50</org_study_id>
    <nct_id>NCT02707393</nct_id>
  </id_info>
  <brief_title>Allogeneic Stem Cell Transplantation for Children With CML</brief_title>
  <official_title>Allogeneic Stem Cell Transplantation for Children and Adolescents With CML: Conditioning Regimen, Donor Selection, Supportive Care and Diagnostic Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Anna Kinderkrebsforschung</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Anna Kinderkrebsforschung</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In children and adolescents with chronic myeloid leukaemia (CML) stem cell transplantation
      (SCT) may be a valid alternative to the life-long treatment with tyrosinkinase inhibitors
      (TKI). This trial aims to evaluate the use of a reduced intensity conditioning regimen (RIC),
      consisting of fludarabine, melphalan and thiotepa in order to minimize transplant related
      mortality and toxic late effects. Strict post-transplant monitoring and reintroduction of TKI
      as well as donor lymphocyte infusions (DLI) in case of relevant residual disease are part of
      the protocol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic myeloid leukaemia (CML) is a rare disease in children with an incidence of 3-5% of
      all paediatric leukaemias. Since the introduction of tyrosinkinase inhibitors (TKI) stem cell
      transplantation (SCT) is no longer the first choice treatment for patients with early phase
      CML.

      However life-long treatment with TKI may not be feasable in several cases due to side effects
      such as growth retardation, non-compliance and resistance. This protocol evaluates the
      feasibility of SCT following a reduced intensity conditioning regimen (RIC) consisting of
      fludarabine, melphalan, thiotepa and thymoglobuline (ATG). Matched siblings and matched
      unrelated donors are permitted for stem cell donation. In case of unrelated donors tissue
      typing has to be done by high resolution molecular typing. Donors with 10/10 or 9/10
      identical allels in the human leukocyte antigen (HLA) system are accepted. Preferred stem
      cell source is bone marrow but peripheral blood stem cells and umbilical cord blood are also
      allowed. Graft-versus-Host-Disease (GvHD)-prophylaxis is achieved with cyclosporine A and
      mycophenolate mofetil.

      Monitoring of the breakpoint cluster region - Abelson (BCR/ABL) rearrangement is performed
      monthly in the first year after SCT. In case of BCR/ABL positivity TKI are given in the first
      year after SCT. Followed by donor lymphocyte infusions (DLI) later on if BCR/ABL positivity
      persists.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>transplant related mortality</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>five years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>event free survival</measure>
    <time_frame>five years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Chronic Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fludarabine intravenous - daily dose: 40mg/sqm on day -7, -6, -5, -4; Thiotepa intravenous - daily dose: 2 x 5mg/kg on day -3; Melphalan intravenous - daily dose: 140/mg/sqm on day - 2; ATG intravenous - dose according to local standards on day -3, -2, -1; bone marrow or peripheral blood stem cells of an HLA identical sibling or matched unrelated donor on day 0; GvHD propyhlaxis with Mycophenolate Mofetil and Cyclosporine A</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>infusion</description>
    <arm_group_label>single arm</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiotepa</intervention_name>
    <description>infusion</description>
    <arm_group_label>single arm</arm_group_label>
    <other_name>Thioplex</other_name>
    <other_name>TESPA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>infusion</description>
    <arm_group_label>single arm</arm_group_label>
    <other_name>Alkeran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATG</intervention_name>
    <description>infusion</description>
    <arm_group_label>single arm</arm_group_label>
    <other_name>Thymoglobulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine A</intervention_name>
    <description>infusion, orally if possible</description>
    <arm_group_label>single arm</arm_group_label>
    <other_name>Sandimmune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil</intervention_name>
    <description>infusion</description>
    <arm_group_label>single arm</arm_group_label>
    <other_name>CellCept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bone marrow or peripheral blood stem cells</intervention_name>
    <description>infusion</description>
    <arm_group_label>single arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  children and adolescents with BCR/ABL positive CML in chronic phase, who are eligible
             for allogeneic stem cell transplantation, irrespective of the previous treatment
             strategy

          -  availability of a HLA matched sibling donor (MSD), a matched family donor, a matched
             unrelated donor or a matched unrelated cord blood (MD)

          -  informed consent

        Exclusion Criteria:

          -  unavailability of MSD or MD

          -  patients in accelerated phase or blast crisis

          -  pregnancy

          -  previous autologous or allogeneic SCT

          -  no informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susanne Matthes, MD</last_name>
    <role>Study Chair</role>
    <affiliation>St. Anna Kinderspital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susanne Matthes, MD</last_name>
    <phone>0043-1-40170</phone>
    <phone_ext>3100</phone_ext>
    <email>susanne.matthes@stanna.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitätsklinik für Kinder- und Jugendheilkunde</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian Urban, Prof., MD</last_name>
      <phone>0043-316-385</phone>
      <phone_ext>3485</phone_ext>
      <email>christian.urban@medunigraz.at</email>
    </contact>
    <investigator>
      <last_name>Christian Urban, Prof., MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Anna Kinderspital</name>
      <address>
        <city>Wien</city>
        <zip>1050</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanne Matthes, MD</last_name>
      <phone>0043-1-40170</phone>
      <phone_ext>3100</phone_ext>
      <email>susanne.matthes@stanna.at</email>
    </contact>
    <contact_backup>
      <last_name>Christina Peters, Prof., MD</last_name>
      <phone>0043-1-40170</phone>
      <phone_ext>3100</phone_ext>
      <email>christina.peters@stanna.at</email>
    </contact_backup>
    <investigator>
      <last_name>Susanne Matthes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Motol, Department of Pediatric Hematology and Oncology, BMT Unit</name>
      <address>
        <city>Praha</city>
        <zip>15006</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petr Sedlacek, MD</last_name>
      <phone>00420-22443</phone>
      <phone_ext>6552</phone_ext>
      <email>Petr.Sedlacek@fnmotol.cz</email>
    </contact>
    <investigator>
      <last_name>Petr Sedlacek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Pediatrica</name>
      <address>
        <city>Monza</city>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adriana Balduzzi, MD</last_name>
      <email>abalduzzi@fondazionembbm.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Czechia</country>
    <country>Italy</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2016</study_first_submitted>
  <study_first_submitted_qc>March 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2016</study_first_posted>
  <last_update_submitted>October 18, 2017</last_update_submitted>
  <last_update_submitted_qc>October 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stem cell transplantation</keyword>
  <keyword>pediatrics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

